In a double‐blind, placebo‐controlled randomized clinical trial (RCT) by Schiavon et al. [43], 30 participants aged 10–25 years with abnormal glucose tolerance (IGT or indeterminate glycemia [INDET]) but without CFRD—17 of whom (57%) were on CFTR modulators—were randomized to receive once‐daily long‐acting insulin, premeal rapid‐acting insulin, or placebo for 4 weeks. This evidence concerns the gene INS and abnormal glucose tolerance.